The latest advances in the use of biological DMARDs to treat Still’s disease

References

• Lee JJY, Schneider R. Systemic juvenile idiopathic arthritis. Pediatr Clin North Am. 2018;65(4):691–709. doi: 10.1016/j.pcl.2018.04.005
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun. 2018;93:24–36. doi: 10.1016/j.jaut.2018.07.018
   PubMed Web of Science ®Google Scholar
• Mitrovic S, Fautrel B. Clinical phenotypes of adult-onset Still’s disease: new insights from pathophysiology and literature findings. J Clin Med. 2021;10(12):2633. doi: 10.3390/jcm10122633
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Natoli V, Consolaro A, et al. Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still’s disease. Rheumatology. 2022;61(10):4124–4129. doi: 10.1093/rheumatology/keac027
   PubMed Web of Science ®Google Scholar
• Ombrello MJ, Remmers EF, Tachmazidou I, et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci USA. 2015;112(52):15970–15975. doi: 10.1073/pnas.1520779112
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Gerfaud-Valentin M, Martinon F, et al. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res. 2015;61(1–2):53–62. doi: 10.1007/s12026-014-8561-9
   PubMed Web of Science ®Google Scholar
• Nirmala N, Brachat A, Feist E, et al. Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015;13(1):50. doi: 10.1186/s12969-015-0047-3
   PubMedGoogle Scholar
• Pay S, Türkçapar N, Kalyoncu M, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25(5):639–644. doi: 10.1007/s10067-005-0138-5
   PubMed Web of Science ®Google Scholar
• Vitale A, Caggiano V, Lopalco G, et al. Still’s disease continuum from childhood to elderly: data from the international AIDA network Still’s disease registry. RMD Open. 2023;9(4):e003578. doi: 10.1136/rmdopen-2023-003578
   PubMed Web of Science ®Google Scholar
• Fautrel B, Mitrovic S, De Matteis A, et al. EULAR/PreS recommendations for the diagnosis and management of systemic juvenile idiopathic arthritis (sJIA) and adult onset Still’s disease (AOSD) [abstract]. Arthritis Rheumatol. 2023;75(suppl 9). [cited Dec 6, 2023]. https://acrabstracts.org/abstract/eular-pres-recommendations-for-the-diagnosis-and-management-of-systemic-juvenile-idiopathic-arthritis-sjia-and-adult-onset-stills-disease-aosd/
   Google Scholar
• Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2022;74(4):553–569. doi: 10.1002/art.42037
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Kontzias A, Hur P, et al. Adult-onset Still’s disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum. 2021;51(4):858–874. doi: 10.1016/j.semarthrit.2021.06.004
   PubMed Web of Science ®Google Scholar
• Hinze CH, Foell D, Kessel C. Treatment of systemic juvenile idiopathic arthritis. Nat Rev Rheumatol. 2023;19(12):778–789. doi: 10.1038/s41584-023-01042-z
   PubMed Web of Science ®Google Scholar
• Di Cola I, Cipriani P, Ruscitti P. Perspectives on the use of non-biological pharmacotherapy for adult-onset Still’s disease. Expert Opin Pharmacother. 2022;23(14):1577–1587. doi: 10.1080/14656566.2022.2126764
   PubMed Web of Science ®Google Scholar
• Galozzi P, Bindoli S, Doria A, et al. Progress in biological therapies for adult-onset Still’s disease. Biologics. 2022;16:21–34. doi: 10.2147/BTT.S290329
   PubMed Web of Science ®Google Scholar
• Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014;66(6):1405–1413. doi: 10.1002/art.38615
   PubMed Web of Science ®Google Scholar
• Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14(10):603–618.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Giacomelli R. Pathogenesis of adult onset Still’s disease: current understanding and new insights. Expert Rev Clin Immunol. 2018;14(11):965–976. doi: 10.1080/1744666X.2018.1533403
   PubMed Web of Science ®Google Scholar
• Vastert SJ, Kuis W, Grom AA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol. 2009;23(5):655–664. doi: 10.1016/j.berh.2009.08.003
   PubMed Web of Science ®Google Scholar
• Nigrovic PA. Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis. Proc Natl Acad Sci USA. 2015;112(52):15785–15786. doi: 10.1073/pnas.1521837113
   PubMed Web of Science ®Google Scholar
• Peckham D, Scambler T, Savic S, et al. The burgeoning field of innate immune-mediated disease and autoinflammation. J Pathol. 2017;241(2):123–139. doi: 10.1002/path.4812
   PubMed Web of Science ®Google Scholar
• Tsuboi H, Segawa S, Yagishita MT, et al. Activation mechanisms of monocytes/macrophages in adult-onset Still disease. Front Immunol. 2022;13:953730. doi: 10.3389/fimmu.2022.953730
   PubMed Web of Science ®Google Scholar
• Ma Y, Wang M, Jia J, et al. Enhanced type I interferon signature induces neutrophil extracellular traps enriched in mitochondrial DNA in adult-onset Still’s disease. J Autoimmun. 2022;127:102793. doi: 10.1016/j.jaut.2022.102793
   PubMed Web of Science ®Google Scholar
• Kim JW, Ahn MH, Jung JY, et al. An update on the pathogenic role of neutrophils in systemic juvenile idiopathic arthritis and adult-onset Still’s disease. Int J Mol Sci. 2021;22(23):13038. doi: 10.3390/ijms222313038
   PubMed Web of Science ®Google Scholar
• Chen PK, Chen DY. An update on the pathogenic role of macrophages in adult-onset Still’s disease and its implication in clinical manifestations and novel therapeutics. J Immunol Res. 2021;2021:8998358. doi: 10.1155/2021/8998358
   PubMed Web of Science ®Google Scholar
• Omoyinmi E, Hamaoui R, Pesenacker A, et al. Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2012;51(10):1881–1886. doi: 10.1093/rheumatology/kes162
   PubMed Web of Science ®Google Scholar
• Chen DY, Chen YM, Chen HH, et al. The associations of circulating CD4 + CD25 high regulatory T cells and TGF-β with disease activity and clinical course in patients with adult-onset Still’s disease. Connect Tissue Res. 2010;51(5):370–377. doi: 10.3109/03008200903461462
   PubMed Web of Science ®Google Scholar
• Henderson LA, Hoyt KJ, Lee PY, et al. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. JCI Insight. 2020;5(6):e132508. doi: 10.1172/jci.insight.132508
   PubMed Web of Science ®Google Scholar
• Aizaki Y, Yazawa H, Sato K, et al. Dual effects of interleukin-10 on natural killer cells and monocytes and the implications for adult-onset Still’s disease. Clin Exp Rheumatol. 2021;39(Suppl 132):22–29. doi: 10.55563/clinexprheumatol/2vdem0
   PubMedGoogle Scholar
• Imbrechts M, Avau A, Vandenhaute J, et al. Insufficient IL-10 production as a mechanism underlying the pathogenesis of systemic juvenile idiopathic arthritis. J Immunol. 2018;201(9):2654–2663. doi: 10.4049/jimmunol.1800468
   PubMed Web of Science ®Google Scholar
• Navarini L, Vomero M, Currado D, et al. The specialized pro-resolving lipid mediator Protectin D1 affects macrophages differentiation and activity in adult-onset Still’s disease and COVID-19, two hyperinflammatory diseases sharing similar transcriptomic profiles. Front Immunol. 2023;14:1148268. doi: 10.3389/fimmu.2023.1148268
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Di Benedetto P, et al. Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? Expert Rev Clin Immunol. 2017;13(11):1041–1047. doi: 10.1080/1744666X.2017.1372194
   PubMed Web of Science ®Google Scholar
• McGonagle D, Ramanan AV, Bridgewood C. Immune cartography of macrophage activation syndrome in the COVID-19 era. Nat Rev Rheumatol. 2021;17(3):145–157. doi: 10.1038/s41584-020-00571-1
   PubMed Web of Science ®Google Scholar
• Rao S, Tsang LS, Zhao M, et al. Adult-onset Still’s disease: a disease at the crossroad of innate immunity and autoimmunity. Front Med. 2022;9:881431. doi: 10.3389/fmed.2022.881431
   Web of Science ®Google Scholar
• Zhou G, Zhou Y, Zhong C, et al. Retrospective analysis of 1,641 cases of classic fever of unknown origin. Ann Transl Med. 2020;8(11):690. doi: 10.21037/atm-20-3875
   PubMed Web of Science ®Google Scholar
• Yachie A. Clinical perspectives and therapeutic strategies: pediatric autoinflammatory disease—a multi-faceted approach to fever of unknown origin of childhood. Inflamm Regen. 2022;42(1):21. doi: 10.1186/s41232-022-00204-y
   PubMed Web of Science ®Google Scholar
• Bilgin E, Hayran M, Erden A, et al. Proposal for a simple algorithm to differentiate adult-onset Still’s disease with other fever of unknown origin causes: a longitudinal prospective study. Clin Rheumatol. 2019;38(6):1699–1706. doi: 10.1007/s10067-019-04455-y
   PubMed Web of Science ®Google Scholar
• Ying S, Lv D, Zhu D, et al. Development and validation of the AF score for diagnosis of adult-onset Still’s disease in fever of unknown origin. J Transl Autoimmun. 2022;6:100184. doi: 10.1016/j.jtauto.2022.100184
   PubMedGoogle Scholar
• Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
   PubMed Web of Science ®Google Scholar
• Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46(2):190–197. doi: 10.3899/jrheum.180168
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–430.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset Still disease. Medicine (Baltimore). 2002;81(3):194–200. doi: 10.1097/00005792-200205000-00003
   PubMed Web of Science ®Google Scholar
• Di Cola I, Bruno F, Berardicurti O, et al. Evaluating the multivisceral involvement on adult-onset Still’s disease to retrieve imaging-based differences in patients with and without macrophage activation syndrome: results from a single-centre observational study. Clin Rheumatol. 2021;40(10):3971–3978. doi: 10.1007/s10067-021-05727-2
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Iacono D, Ciccia F, et al. Macrophage activation syndrome in patients affected by adult-onset Still disease: analysis of survival rates and predictive factors in the gruppo italiano di ricerca in reumatologia clinica e sperimentale cohort. J Rheumatol. 2018;45(6):864–872. doi: 10.3899/jrheum.170955
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Masedu F, et al. Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14(1):194. doi: 10.1186/s12916-016-0738-8
   PubMed Web of Science ®Google Scholar
• Tibaldi J, Pistorio A, Aldera E, et al. Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2020;59(11):3505–3514. doi: 10.1093/rheumatology/keaa240
   PubMed Web of Science ®Google Scholar
• Zhu D, Meng J, Jia J, et al. Performance of the modified systemic manifestation score for systemic juvenile idiopathic arthritis in adult-onset Still’s disease. Clin Rheumatol. 2023;42(1):187–195. doi: 10.1007/s10067-022-06340-7
   PubMed Web of Science ®Google Scholar
• Mitrovic S, Fautrel B. Complications of adult-onset Still’s disease and their management. Expert Rev Clin Immunol. 2018;14(5):351–365. doi: 10.1080/1744666X.2018.1465821
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Ursini F, Berardicurti O, et al. Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still’s disease. Rheumatology (Oxford). 2022;62(1):321–329. doi: 10.1093/rheumatology/keac247
   PubMed Web of Science ®Google Scholar
• Saper VE, Chen G, Deutsch GH, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019;78(12):1722–1731. doi: 10.1136/annrheumdis-2019-216040
   PubMed Web of Science ®Google Scholar
• Schulert GS, Yasin S, Carey B, et al. Systemic juvenile idiopathic arthritis–associated lung disease: characterization and risk factors. Arthritis & Rheumat. 2019;71(11):1943–1954. doi: 10.1002/art.41073
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Berardicurti O, Iacono D, et al. Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity—characterisation and predictive factors from gruppo italiano di ricerca in reumatologia clinica e sperimentale (GIRRCS) cohort of patients. Arthritis Res Ther. 2020;22(1):151. doi: 10.1186/s13075-020-02245-5
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Berardicurti O, Giacomelli R, et al. The clinical heterogeneity of adult onset Still’s disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients. Semin Immunol. 2021;58:101632. doi: 10.1016/j.smim.2022.101632
   PubMed Web of Science ®Google Scholar
• Maria AT, Le Quellec A, Jorgensen C, et al. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13:1149–1159. doi: 10.1016/j.autrev.2014.08.032
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Furuta S, Hiraguri M, et al. Latent class analysis of 216 patients with adult-onset Still’s disease. Arthritis Res Ther. 2022;24(1):7. doi: 10.1186/s13075-021-02708-3
   PubMedGoogle Scholar
• Li R, Liu X, Chen G, et al. Clinical phenotypes and prognostic factors of adult-onset Still’s disease: data from a large inpatient cohort. Arthritis Res Ther. 2021;23(1):300. doi: 10.1186/s13075-021-02688-4
   PubMed Web of Science ®Google Scholar
• Wahbi A, Tessoulin B, Bretonnière C, et al. Catastrophic adult-onset Still’s disease as a distinct life-threatening clinical subset: case–control study with dimension reduction analysis. Arthritis Res Ther. 2021;23(1):256. doi: 10.1186/s13075-021-02631-7
   PubMed Web of Science ®Google Scholar
• Berardicurti O, Conforti A, Iacono D, et al. Dissecting the clinical heterogeneity of adult-onset Still’s disease: results from a multi-dimensional characterization and stratification. Rheumatology (Oxford). 2021;60(10):4844–4849. doi: 10.1093/rheumatology/keaa904
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Masedu F, Vitale A, et al. Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA network Still disease registry. RMD Open. 2023;9(4):e003419. doi: 10.1136/rmdopen-2023-003419
   PubMedGoogle Scholar
• Mitrovic S, Hassold N, Kamissoko A, et al. Adult-onset Still’s disease or systemic-onset juvenile idiopathic arthritis and spondyloarthritis: overlapping syndrome or phenotype shift? Rheumatology (Oxford). 2022;61(6):2535–2547. doi: 10.1093/rheumatology/keab726
   PubMed Web of Science ®Google Scholar
• Myachikova V, Moiseeva O, Konradi A, et al. A retrospective analysis of colchicine in combination with NSAIDs therapy in patients with systemic form of adult-onset Still’s disease with serositis. Clin Exp Rheumatol. 2022;40:1474–1479. doi: 10.55563/clinexprheumatol/1o41c8
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Liakouli V, et al. Managing adult-onset still’s disease: the effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission results from an observational study. Medicine (Baltimore). 2019;98(15):e15123. doi: 10.1097/MD.0000000000015123
   PubMed Web of Science ®Google Scholar
• Kondo F, Sugihara T, Umezawa N, et al. Associated factors with poor treatment response to initial glucocorticoid therapy in patients with adult-onset Still’s disease. Arthritis Res Ther. 2022;24(1):92. doi: 10.1186/s13075-022-02780-3
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Sota J, Vitale A, et al. The administration of methotrexate in patients with Still’s disease, “real-life” findings from AIDA network Still disease registry. Semin Arthritis Rheum. 2023;62:152244. doi: 10.1016/j.semarthrit.2023.152244
   PubMed Web of Science ®Google Scholar
• Nakamura H, Fujieda Y, Tarumi M, et al. Calcineurin inhibitors for adult-onset Still’s disease: a multicentre retrospective cohort study. Clin Exp Rheumatol. 2020;38(Suppl 127):11–16.
   PubMedGoogle Scholar
• Leavis HL, van Daele PLA, Mulders-Manders C, et al. Management of adult-onset Still’s disease: evidence- and consensus-based recommendations by experts. Rheumatology (Oxford). 2023 Sep 5;kead461. doi: 10.1093/rheumatology/kead461
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Caporali R, Ciccia F, et al. Expert consensus on the treatment of patients with adult-onset Still’s disease with the goal of achieving an early and long-term remission. Autoimmun Rev. 2023;22(12):103400. doi: 10.1016/j.autrev.2023.103400
   PubMed Web of Science ®Google Scholar
• Kedor C, Tomaras S, Baeumer D, et al. Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review. Ther Adv Musculoskelet Dis. 2021;13:1759720X211059598. doi: 10.1177/1759720X211059598
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Sota J, Ruscitti P, et al. The treatment of adult-onset Still’s disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. Clin Exp Rheumatol. 2021;39(1):187–195. doi: 10.55563/clinexprheumatol/fsq5vq
   PubMed Web of Science ®Google Scholar
• Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with Still’s disease. Rheumatology (Oxford). 2019;58(Supplement_6):vi9–vi22. doi: 10.1093/rheumatology/kez350
   PubMedGoogle Scholar
• Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2007;67(3):302–308. doi: 10.1136/ard.2007.076034
   PubMed Web of Science ®Google Scholar
• Nordström D, KNIGHT A, LUUKKAINEN R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol. 2012;39(10):2008–2011. doi: 10.3899/jrheum.111549
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, et al. Efficacy of anakinra in refractory adult-onset Still’s disease. Medicine. 2015;94(39):e1554. doi: 10.1097/MD.0000000000001554
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Priori R, Valesini G, et al. Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still’s disease: a multicentre retrospective observational study. Front Pharmacol. 2017;8:369. doi: 10.3389/fphar.2017.00369
   PubMed Web of Science ®Google Scholar
• Giancane G, Papa R, Vastert S, et al. Anakinra in patients with systemic juvenile idiopathic arthritis: long-term safety from the pharmachild registry. J Rheumatol. 2022;49(4):398–407. doi: 10.3899/jrheum.210563
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Ursini F, Sota J, et al. The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still’s disease. A systematic review and meta-analysis of observational studies. Ther Adv Musculoskelet Dis. 2020;12:1759720X20933133. doi: 10.1177/1759720X20933133
   PubMed Web of Science ®Google Scholar
• Berardicurti O, Ruscitti P, Pavlych V, et al. Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy. Expert Rev Clin Pharmacol. 2020;13(6):593–604. doi: 10.1080/17512433.2020.1772055
   PubMed Web of Science ®Google Scholar
• Vitale A, Cavalli G, Colafrancesco S, et al. Long-term retention rate of Anakinra in adult onset Still’s disease and predictive factors for treatment response. Front Pharmacol. 2019;10:296. doi: 10.3389/fphar.2019.00296
   PubMed Web of Science ®Google Scholar
• Sota J, Rigante D, Ruscitti P, et al. Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset Still disease. Front Pharmacol. 2019;10:918. doi: 10.3389/fphar.2019.00918
   PubMed Web of Science ®Google Scholar
• Vitale A, Cavalli G, Ruscitti P, et al. Comparison of early vs. Delayed anakinra treatment in patients with adult onset Still’s disease and effect on clinical and laboratory outcomes. Front Med. 2020;7:42. doi: 10.3389/fmed.2020.00042
   PubMed Web of Science ®Google Scholar
• Nigrovic PA, Mannion M, Prince FHM, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545–555. doi: 10.1002/art.30128
   PubMed Web of Science ®Google Scholar
• Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis & Rheumat. 2014;66(4):1034–1043. doi: 10.1002/art.38296
   PubMed Web of Science ®Google Scholar
• Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol. 2019;71(7):1163–1173. doi: 10.1002/art.40865
   PubMed Web of Science ®Google Scholar
• Erkens RGA, Calis JJA, Verwoerd A, et al. Recombinant interleukin-1 receptor antagonist is an effective first-line treatment strategy in new-onset systemic juvenile idiopathic arthritis, irrespective of HLA-DRB1 background and IL1RN variants. Arthritis Rheumatol. 2023 Jul 20;76(1): 119–129. Epub ahead of print. 10.1002/art.42656
   PubMed Web of Science ®Google Scholar
• Arthur VL, Shuldiner E, Remmers EF, et al. IL1RN variation influences both disease susceptibility and response to recombinant human interleukin-1 receptor antagonist therapy in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2018;70(8):1319–1330. doi: 10.1002/art.40498
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396–2406. doi: 10.1056/NEJMoa1205099
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis. 2018;77(12):1710–1719. doi: 10.1136/annrheumdis-2018-213150
   PubMed Web of Science ®Google Scholar
• Quartier P, Alexeeva E, Constantin T, et al. Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb/IV open-label, randomized study. Arthritis Rheumatol. 2021;73(2):336–346. doi: 10.1002/art.41488
   PubMed Web of Science ®Google Scholar
• Alexeeva E, Krekhova E, Dvoryakovskaya T, et al. Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: a single-centre cohort study using routinely collected health data. Front Pediatr. 2023;11:1114207. doi: 10.3389/fped.2023.1114207
   PubMed Web of Science ®Google Scholar
• Kedor C, Listing J, Zernicke J, et al. Canakinumab for treatment of adult-onset Still’s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis. 2020;79(8):1090–1097. doi: 10.1136/annrheumdis-2020-217155
   PubMed Web of Science ®Google Scholar
• Vitale A, Caggiano V, Maggio MC, et al. Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: real-life experience from the international AIDA registry. Front Med. 2022;9:1071732. doi: 10.3389/fmed.2022.1071732
   Web of Science ®Google Scholar
• Laskari K, Tektonidou MG, Katsiari C, et al. Outcome of refractory to conventional and/or biologic treatment adult Still’s disease following canakinumab treatment: countrywide data in 50 patients. Semin Arthritis Rheum. 2021;51(1):137–143. doi: 10.1016/j.semarthrit.2020.10.011
   PubMed Web of Science ®Google Scholar
• Brachat AH, Grom AA, Wulffraat N, et al. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Res Ther. 2017;19(1):13. doi: 10.1186/s13075-016-1212-x
   PubMedGoogle Scholar
• Verweyen EL, Pickering A, Grom AA, et al. Distinct gene expression signatures characterize strong clinical responders versus nonresponders to canakinumab in children with systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2021;73(7):1334–1340. doi: 10.1002/art.41640
   PubMed Web of Science ®Google Scholar
• Ghannam K, Zernicke J, Kedor C, et al. Distinct effects of interleukin-1β inhibition upon cytokine profile in patients with adult-onset Still’s disease and active articular manifestation responding to canakinumab. J Clin Med. 2021;10(19):10. doi: 10.3390/jcm10194400
   Web of Science ®Google Scholar
• Kishimoto T, Kang S. IL-6 revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19. Annu Rev Immunol. 40(1): Epub 2022 Feb 3. PMID: 35113729:323–348. 2022 Apr 26. 10.1146/annurev-immunol-101220-023458
   PubMedGoogle Scholar
• Choy EH, De Benedetti F, Takeuchi T, et al. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335–345. doi: 10.1038/s41584-020-0419-z
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–2395. doi: 10.1056/NEJMoa1112802
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77(12):1720–1729. doi: 10.1136/annrheumdis-2018-213920
   PubMed Web of Science ®Google Scholar
• Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol. 2014;33(1):49–55. doi: 10.1007/s10067-013-2381-5
   PubMed Web of Science ®Google Scholar
• Sota J, Vitale A, Lopalco G, et al. Efficacy and safety of tocilizumab in adult-onset Still’s disease: real-life experience from the international AIDA registry. Semin Arthritis Rheum. 2022;57:152089. doi: 10.1016/j.semarthrit.2022.152089
   PubMed Web of Science ®Google Scholar
• Reihl Crnogaj M, Čubelić D, Babić A, et al. Treatment of refractory adult onset Still’s disease with tocilizumab—a single centre experience and literature review. Rheumatol Int. 2020;40(8):1317–1325. doi: 10.1007/s00296-020-04622-4
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment–refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis & Rheumat. 2014;66(6):1659–1665. doi: 10.1002/art.38398
   PubMed Web of Science ®Google Scholar
• Elkayam O, Jiries N, Dranitzki Z, et al. Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol. 2014;41(2):244–247. doi: 10.3899/jrheum.130881
   PubMed Web of Science ®Google Scholar
• Ma Y, Wu M, Zhang X, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still’s disease: a meta-analysis. Mod Rheumatol. 2018;28(5):849–857. doi: 10.1080/14397595.2017.1416924
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Liakouli V, et al. Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort. Rheumatol Int. 2020;40(1):107–113. doi: 10.1007/s00296-019-04358-w
   PubMed Web of Science ®Google Scholar
• Pacharapakornpong T, Vallibhakara S-O, Lerkvaleekul B, et al. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis. Rheumatol Int. 2017;37(2):251–255. doi: 10.1007/s00296-016-3595-z
   PubMed Web of Science ®Google Scholar
• Yan X, Tang W, Zhang Z, et al. Tocilizumab in systemic juvenile idiopathic arthritis: response differs by disease duration at medication initiation and by phenotype of disease. Front Pediatr. 2021;9:735846. doi: 10.3389/fped.2021.735846
   PubMed Web of Science ®Google Scholar
• Nada DW, Moghazy A, Allam A-S, et al. Short-term outcomes and predictors of effectiveness of tocilizumab in systemic juvenile idiopathic arthritis: a prospective cohort study. Front Med. 2021;8:665028. doi: 10.3389/fmed.2021.665028
   Web of Science ®Google Scholar
• Kaneko Y, Takeuchi T. Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease. Expert Opin Biol Ther. 2022;22(1):79–85. doi: 10.1080/14712598.2021.1942832
   PubMed Web of Science ®Google Scholar
• Aletaha D, Kerschbaumer A, Kastrati K, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann Rheum Dis. 2023;82(6):773–787. doi: 10.1136/ard-2022-222784
   PubMed Web of Science ®Google Scholar
• Huang Y, Sompii-Montgomery L, Patti J, et al. Disease course, treatments, and outcomes of children with systemic juvenile idiopathic arthritis-associated lung disease. Arthritis Care Res (Hoboken). Epub ahead of print. 2023 Sep 10. doi:10.1002/acr.25234
   Web of Science ®Google Scholar
• Saper VE, Ombrello MJ, Tremoulet AH, et al. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Ann Rheum Dis. 2022;81(3):406–415. doi: 10.1136/annrheumdis-2021-220578
   PubMed Web of Science ®Google Scholar
• Binstadt BA, Nigrovic PA. The conundrum of lung disease and drug hypersensitivity-like reactions in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2022;74:1122–1131.
   PubMed Web of Science ®Google Scholar
• Nigrovic PA. Storm warning: lung disease in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2019;71(11):1773–1775. doi: 10.1002/art.41071
   PubMed Web of Science ®Google Scholar
• Wobma H, Bachrach R, Farrell J, et al. Development of a screening algorithm for lung disease in systemic juvenile idiopathic arthritis. ACR Open Rheumatol. 2023;5(10):556–562. doi: 10.1002/acr2.11600
   PubMedGoogle Scholar
• Girard-Guyonvarc’h C, Harel M, Gabay C. The role of interleukin 18/Interleukin 18-binding protein in adult-onset Still’s disease and systemic juvenile idiopathic arthritis. J Clin Med. 2022;11(2):11. doi: 10.3390/jcm11020430
   Web of Science ®Google Scholar
• Gabay C, Fautrel B, Rech J, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis. 2018;77:840–847. doi: 10.1136/annrheumdis-2017-212608
   PubMed Web of Science ®Google Scholar
• Kiltz U, Kiefer D, Braun J, et al. Prolonged treatment with Tadekinig alfa in adult-onset Still’s disease. Ann Rheum Dis. 2020;79(1):e10. doi: 10.1136/annrheumdis-2018-214496
   PubMed Web of Science ®Google Scholar
• Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020;382(19):1811–1822. doi: 10.1056/NEJMoa1911326
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Prencipe G, Bracaglia C, et al. Targeting interferon-γ in hyperinflammation: opportunities and challenges. Nat Rev Rheumatol. 2021;17(11):678–691. doi: 10.1038/s41584-021-00694-z
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Grom AA, Brogan PA, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023;82(6):857–865. doi: 10.1136/ard-2022-223739
   PubMed Web of Science ®Google Scholar
• Favoino E, Prete M, Catacchio G, et al. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart? Autoimmun Rev. 2021;20(3):102750. doi: 10.1016/j.autrev.2021.102750
   PubMed Web of Science ®Google Scholar
• He T, Xia Y, Luo Y, et al. JAK inhibitors in systemic juvenile idiopathic arthritis. Front Pediatr. 2023;11:1134312. doi: 10.3389/fped.2023.1134312
   PubMed Web of Science ®Google Scholar
• Hu Q, Wang M, Jia J, et al. Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China. Ann Rheum Dis. 2020;79(6):842–844. doi: 10.1136/annrheumdis-2019-216699
   PubMed Web of Science ®Google Scholar
• Gillard L, Pouchot J, Cohen-Aubart F, et al. JAK inhibitors in difficult-to-treat adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2023;62(4):1594–1604. doi: 10.1093/rheumatology/keac440
   PubMed Web of Science ®Google Scholar
• Furuya MY, Asano T, Sumichika Y, et al. Tofacitinib inhibits granulocyte–macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils. Arthritis Res Ther. 2018;20(1):196. doi: 10.1186/s13075-018-1685-x
   PubMedGoogle Scholar
• Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019;6(12):e630–e637. doi: 10.1016/S2352-3026(19)30156-5
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang R, Wu X, et al. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial. Br J Haematol. 2021;193(4):761–768. doi: 10.1111/bjh.17331
   PubMed Web of Science ®Google Scholar
• Huang Z, You X, Chen L, et al. mTORC1 links pathology in experimental models of Still’s disease and macrophage activation syndrome. Nat Commun. 2022;13(1):6915. doi: 10.1038/s41467-022-34480-6
   PubMed Web of Science ®Google Scholar
• Jia J, Wang M, Meng J, et al. Ferritin triggers neutrophil extracellular trap-mediated cytokine storm through Msr1 contributing to adult-onset Still’s disease pathogenesis. Nat Commun. 2022;13(1):6804. doi: 10.1038/s41467-022-34560-7
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Di Cola I, Di Muzio C, et al. Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications. Autoimmun Rev. 2022;21(7):103114. doi: 10.1016/j.autrev.2022.103114
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Ursini F, Cipriani P, et al. Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies. Expert Rev Clin Immunol. 2017;13(11):1089–1097. doi: 10.1080/1744666X.2017.1375853
   PubMed Web of Science ®Google Scholar
• Fautrel B, Patterson J, Bowe C, et al. Systematic review on the use of biologics in adult-onset Still’s disease. Semin Arthritis Rheum. 2023 Feb;58:152139. Epub 2022 Nov 17. PMID: 364422: doi: 10.1016/j.semarthrit.2022.152139
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Afeltra A, Alunno A, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017;16(9):911–924. doi: 10.1016/j.autrev.2017.07.012
   PubMed Web of Science ®Google Scholar
• Inoue N, Schulert GS. Mouse models of systemic juvenile idiopathic arthritis and macrophage activation syndrome. Arthritis Res Ther. 2023;25(1):48.
   PubMed Web of Science ®Google Scholar
• Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016;75(8):1428–1437. doi: 10.1136/annrheumdis-2016-209201
   PubMed Web of Science ®Google Scholar
• Shakoory B, Geerlinks A, Wilejto M, et al. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis. 2023;82(10):1271–1285. doi: 10.1136/ard-2023-224123
   PubMed Web of Science ®Google Scholar
• Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259–68. doi: 10.1038/nrrheum.2015.179
   PubMed Web of Science ®Google Scholar
• Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra sepsis syndrome study group. JAMA. 1994;271(23):1836–1843. doi: 10.1001/jama.1994.03510470040032
   PubMed Web of Science ®Google Scholar
• Eloseily EM, Weiser P, Crayne CB, et al. Benefit of Anakinra in treating pediatric secondary Hemophagocytic Lymphohistiocytosis. Arthritis Rheumatol. 2020;72(2):326–334. doi: 10.1002/art.41103
   PubMed Web of Science ®Google Scholar
• Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44(2):275–281. doi: 10.1097/CCM.0000000000001402
   PubMed Web of Science ®Google Scholar
• Yasin S, Solomon K, Canna SW, et al. IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. Rheumatology. 2020;59(2):442–445. doi: 10.1093/rheumatology/kez284
   PubMed Web of Science ®Google Scholar
• Rood JE, Rezk A, Pogoriler J, et al. Improvement of refractory systemic juvenile idiopathic arthritis-associated lung disease with single-agent blockade of IL-1β and IL-18. J Clin Immunol. 2023;43(1):101–108. doi: 10.1007/s10875-022-01353-y
   PubMed Web of Science ®Google Scholar
• Wu J, Sun L, Tang X, et al. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis–associated refractory macrophage activation syndrome. Mod Rheumatol. 2022;32(6):1114–1121. doi: 10.1093/mr/roab119
   PubMed Web of Science ®Google Scholar
• Shimizu M, Mizuta M, Okamoto N, et al. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatr Rheumatol. 2020;18(1):2. doi: 10.1186/s12969-020-0399-1
   PubMed Web of Science ®Google Scholar
• Lenert A, Oh G, Ombrello MJ, et al. Clinical characteristics and comorbidities in adult-onset Still’s disease using a large US administrative claims database. Rheumatology (Oxford). 2020;59:1725–1733. doi: 10.1093/rheumatology/kez622
   PubMed Web of Science ®Google Scholar
• Di Cola I, Iacono D, Pantano I, et al. Clinical characteristics of obese patients with adult-onset Still’s disease. Data from a large multicentre cohort. Joint Bone Spine. 2023;90(5):105576. doi: 10.1016/j.jbspin.2023.105576
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Di Cola I, Berardicurti O, et al. Impact of smoking habit on adult-onset Still’s disease prognosis, findings from a multicentre observational study. Clin Rheumatol. 2022;41(3):641–647. doi: 10.1007/s10067-021-05929-8
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Bruno F, Berardicurti O, et al. Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences. Ann Rheum Dis. 2020;79(9):1152–1155. doi: 10.1136/annrheumdis-2020-218048
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Ciccia F, et al. Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers. Autoimmun Rev. 2017;16(1):16–21. doi: 10.1016/j.autrev.2016.09.016
   PubMed Web of Science ®Google Scholar
• Di Cola I, Di Muzio C, Conforti A, et al. Adult-onset Still’s disease with elderly onset: results from a multicentre study. Clin Exp Rheumatol. 2022;40:1517–1525. doi: 10.55563/clinexprheumatol/0215kv
   PubMed Web of Science ®Google Scholar